Erlotinib

Pre-clinicalCompleted

0 watching 0 views this week💤 Quiet

Hype Score

Development Stage

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Nonsquamous Nonsmall Cell Neoplasm of Lung

Conditions

Nonsquamous Nonsmall Cell Neoplasm of Lung

Trial Timeline

Apr 1, 2008 → Aug 1, 2012

NCT ID

NCT01161173

About Erlotinib

Erlotinib is a pre-clinical stage product being developed by Roche for Nonsquamous Nonsmall Cell Neoplasm of Lung. The current trial status is completed. This product is registered under clinical trial identifier NCT01161173. Target conditions include Nonsquamous Nonsmall Cell Neoplasm of Lung.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (17)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01990261	Pre-clinical	Terminated	May 1, 2013	Sep 1, 2014	Non-Squamous Non-Small Cell Lung Cancer
NCT01667562	Phase 3	Completed	Jan 20, 2012	Sep 7, 2017	Non-Small Cell Lung Cancer
NCT01470716	Phase 2	UNKNOWN	Jan 1, 2012	Jun 30, 2022	NSCLC Stage II
NCT01664533	Pre-clinical	Completed	Sep 1, 2011	Aug 1, 2013	Non-Squamous Non-Small Cell Lung Cancer
NCT01153984	Phase 2	Completed	Jun 1, 2011	Jul 1, 2015	Carcinoma，Non-Small-Cell Lung
NCT01310036	Phase 2	Completed	Apr 30, 2011	Dec 30, 2016	Non-Squamous Non-Small Cell Lung Cancer
NCT01378962	Phase 2	Completed	Mar 31, 2011	Jan 31, 2017	Non-Squamous Non-Small Cell Lung Cancer
NCT01260181	Phase 2	Completed	Mar 31, 2011	Sep 29, 2017	Non-Squamous Non-Small Cell Lung Cancer
NCT01230710	Approved	Completed	Mar 1, 2011	Sep 1, 2013	Non-Small Cell Lung Cancer
NCT01085838	Phase 1/2	Completed	Jul 1, 2010	Mar 1, 2014	Myelodysplastic Syndrome
NCT02595450	Pre-clinical	Completed	Sep 1, 2008	Nov 1, 2014	Non-Small Cell Lung Cancer
NCT01161173	Pre-clinical	Completed	Apr 1, 2008	Aug 1, 2012	Nonsquamous Nonsmall Cell Neoplasm of Lung
NCT00452075	Phase 2	Terminated	Mar 1, 2007	Aug 1, 2010	Non Small Cell Lung Cancer
NCT00391248	Phase 2	Completed	Nov 1, 2006	Dec 1, 2012	Non-small Cell Lung Cancer
NCT00339586	Phase 2	UNKNOWN	Jan 1, 2006	—	Lung Neoplasms
NCT02774278	Phase 2	Completed	Jul 1, 2005	Jun 1, 2009	Non-Squamous Non-Small Cell Lung Cancer
NCT00949910	Approved	Completed	Nov 1, 2004	Apr 1, 2009	Non-Small Cell Lung Cancer

Competing Products

7 competing products in Nonsquamous Nonsmall Cell Neoplasm of Lung

See all competitors

Product	Company	Stage	Hype Score
Pemetrexed + Erlotinib + Pemetrexed + Erlotinib	Eli Lilly	Phase 2	52
Patritumab Deruxtecan + Platinum-based chemotherapy	Daiichi Sankyo	Phase 3	77
Pembrolizumab + Carboplatin + Cisplatin + Pemetrexed + Lenvatinib + Placebo matching lenvatinib	Eisai	Phase 3	77
Pembrolizumab + Carboplatin + Cisplatin + Pemetrexed + Lenvatinib + Placebo matching lenvatinib	Eisai	Phase 3	77
Pemetrexed	Eli Lilly	Phase 2	52
Pembrolizumab + Pemetrexed + Carboplatin + Cisplatin + Olaparib	Merck	Phase 3	77
Pemetrexed + Carboplatin + demcizumab	Mereo BioPharma	Phase 2	44

Other Products from Roche

EmicizumabApproved

rituximab + methotrexate + methylprednisolone + acetaminophen + antihistamineApproved

RituximabApproved

mycophenolate mofetil [CellCept]Approved

saquinavir/ritonavir + atazanavir/ritonavirApproved